Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria
Under a Creative Commons license
open access
Abbreviations
AE
adverse event
ANCOVA
analysis of covariance
BMI
body mass index
BOCF
baseline-observation-carried-forward
CIU
chronic idiopathic urticaria
CSU
chronic spontaneous urticaria
DLQI
Dermatology Life Quality Index
EAACI
European Academy of Allergy & Clinical Immunology
EDF
European Dermatology Forum
FAS
full analysis set
GA2LEN
Global Allergy and Asthma European Network
H1AH
H1 antihistamine
IRT
interactive response technology
JDA
Japanese Dermatological Association
LOCF
last-observation-carried-forward
LS
least-squares
LTRA
leukotriene receptor antagonist
MID
minimally important difference
MMRM
mixed model with repeated measures
PPS
per-protocol set
QoL
quality of life
SAE
serious adverse event
SAF
safety set
SE
standard error
UAS
urticaria activity score
WAO
World Allergy Organization
Keywords
Antihistamines
Chronic spontaneous urticaria
Japan
Korea
Omalizumab
Cited by (0)
- 1
These two authors contributed equally to this work.
- 2
Present address: 419 Everson Place, Westfield, NJ 07090, USA.
© 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of Japanese Society for Investigative Dermatology.